Chargement en cours...
Risk-Benefit Profiles of Women Using Tamoxifen for Chemoprevention
BACKGROUND: Tamoxifen has been US Food and Drug Administration–approved for primary prevention of breast cancer since 1998 but has not been widely adopted, in part because of increased risk of serious side effects. Little is known about the risk-benefit profiles of women who use chemoprevention outs...
Enregistré dans:
| Publié dans: | J Natl Cancer Inst |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4296193/ https://ncbi.nlm.nih.gov/pubmed/25475563 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/dju354 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|